跳至主要内容
临床试验/NCT00123175
NCT00123175撤回1 期

Levonorgestrel Containing Intrauterine Device in the Treatment of Endometrial Hyperplasia Without Atypia

Milton S. Hershey Medical Center0 个研究点开始时间: 2009年9月最近更新:
适应症

试验速览

阶段
1 期
状态
撤回
主要终点
Pathologic examination of the specimens obtained by endometrial biopsy to determine the regression of endometrial hyperplasia without atypia compared to Provera

研究概览

简要总结

The purpose of this research is to determine the effectiveness of the intrauterine device (IUD) called Mirena when compared to the Provera tablets used in treating this condition.

详细描述

Endometrial hyperplasia without atypia is a condition usually caused by excessive stimulation of the uterine lining (endometrium) by estrogens, and may cause irregular bleeding as a presenting symptom, but rarely may progress to endometrial cancer, which makes treatment important. The only treatment approved so far is medroxyprogesterone acetate tablets (progesterone), also known as Provera.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Histologic diagnosis of simple or complex endometrial hyperplasia without atypia
  • Normal pap smear within one year

排除标准

  • Family history of endometrial cancer
  • Contraindications for the intrauterine device

结局指标

主要结局

Pathologic examination of the specimens obtained by endometrial biopsy to determine the regression of endometrial hyperplasia without atypia compared to Provera

时间窗: 90 days

次要结局

  • Side effects(90 days)
  • Bleeding profile(90 days)
  • Estradiol and progesterone levels(90 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Richard S. Legro, M.D.

Professor, Obstetrics and Gynecology and Public Health Sciences

Milton S. Hershey Medical Center

相似试验

Treatment of Endometrial Hyperplasia With an... | 临床试验